Literature DB >> 28560220

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Nicolò Scuderi1, Ambra Monfrecola1, Luca Andrea Dessy1, Gabriella Fabbrocini2, Matteo Megna2, Giuseppe Monfrecola2.   

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. The central pathogenic event in HS is believed to be the occlusion of the upper part of the folliculopilosebaceous unit, leading to the rupture of the sebofollicular canal with the consequent development of perifollicular lymphohistiocytic inflammation. The HS treatment choices are influenced by disease severity and its individual subjective impact, involving both medical and surgical interventions. However, given the chronic nature of HS, its destructive impact on social, working, and daily life of patients, its management is often frustrating for both the patient and physician. Hence, prompt and effective management strategies are urgently needed and a multidisciplinary approach is advocated. Therefore, in this article, we highlighted the main features of HS (clinical aspects, epidemiology, pathogenesis, diagnostic criteria, classifications, comorbidities, and treatments), so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation (inflammatory nodules, abscesses, sinus tract, etc.).

Entities:  

Keywords:  Diagnosis; Hidradenitis suppurativa; Pathogenesis; Surgical approach; Treatment

Year:  2017        PMID: 28560220      PMCID: PMC5436059          DOI: 10.1159/000462979

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  152 in total

1.  Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.

Authors:  C O Mendonça; C E M Griffiths
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

2.  Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells.

Authors:  F Re; J L Strominger
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

Review 3.  Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.

Authors:  Pia Haslund; Robert A Lee; Gregor B E Jemec
Journal:  Acta Derm Venereol       Date:  2009-11       Impact factor: 4.437

4.  Surgical treatment of perianal and perineal hidradenitis suppurativa.

Authors:  J P Thornton; H Abcarian
Journal:  Dis Colon Rectum       Date:  1978 Nov-Dec       Impact factor: 4.585

5.  A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Authors:  I Miller; C D Lynggaard; S Lophaven; C Zachariae; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2011-06-30       Impact factor: 9.302

Review 6.  γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis.

Authors:  Andrew E Pink; Michael A Simpson; Nemesha Desai; Richard C Trembath; Jonathan N W Barker
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

7.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

8.  The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities.

Authors:  V Bettoli; S Pasquinucci; S Caracciolo; D Piccolo; S Cazzaniga; F Fantini; L Binello; G Pintori; L Naldi
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-05-02       Impact factor: 6.166

9.  Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity.

Authors:  Florence Canoui-Poitrine; Jean E Revuz; Pierre Wolkenstein; Cédric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

10.  Islanded perforator flaps in the reconstruction of hidradenitis suppurativa defects.

Authors:  Onur Egemen; Özay Özkaya; Derya Bingöl; Çağdaş Orman; Mithat Akan
Journal:  J Reconstr Microsurg       Date:  2013-01-09       Impact factor: 2.873

View more
  9 in total

1.  Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision.

Authors:  Ledibabari M Ngaage; Yinglun Wu; Shealinna Ge; Selim Gebran; Fan Liang; Erin M Rada; Arthur J Nam; Ronald P Silverman; Yvonne M Rasko
Journal:  Int Wound J       Date:  2019-11-03       Impact factor: 3.315

Review 2.  Surgical Management of Hidradenitis Suppurativa: A Narrative Review.

Authors:  Surbhi Chawla; Connor Toale; Marie Morris; A M Tobin; Dara Kavanagh
Journal:  J Clin Aesthet Dermatol       Date:  2022-01

Review 3.  Hidradenitis Suppurativa: Surgical and Postsurgical Management.

Authors:  Marco Manfredini; Federico Garbarino; Laura Bigi; Giovanni Pellacani; Cristina Magnoni
Journal:  Skin Appendage Disord       Date:  2020-05-14

Review 4.  Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil.

Authors:  Maria Cecilia Rivitti-Machado; Renata Ferreira Magalhães; Roberto Souto da Silva; Gleison V Duarte; Fabiana Zs Bosnich; Roberto Gaspar Tunala; Francisco José Forestiero
Journal:  Drugs Context       Date:  2022-01-19

5.  Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.

Authors:  Afsaneh Alavi; Iltefat Hamzavi; Kurt Brown; Leandro L Santos; Zhaoyin Zhu; Huiqing Liu; Michael D Howell; Joslyn S Kirby
Journal:  Br J Dermatol       Date:  2022-03-06       Impact factor: 11.113

6.  Co-Graft of Acellular Dermal Matrix and Split Thickness Skin Graft-A New Reconstructive Surgical Method in the Treatment of Hidradenitis Suppurativa.

Authors:  Marcin Gierek; Wojciech Łabuś; Anna Słaboń; Karolina Ziółkowska; Gabriela Ochała-Gierek; Diana Kitala; Karol Szyluk; Paweł Niemiec
Journal:  Bioengineering (Basel)       Date:  2022-08-14

7.  Outcome Comparison of Different Reconstructive Approaches for Axillary Defects Secondary to Radical Excision of Hidradenitis Suppurativa.

Authors:  Vlad Tereshenko; Riccardo Schweizer; Matthias Waldner; Bong-Sung Kim; Pietro Giovanoli; Holger Jan Klein
Journal:  Dermatology       Date:  2022-01-27       Impact factor: 5.197

8.  Intralesional Diode Laser 1064 nm for the Treatment of Hidradenitis Suppurativa: A Report of Twenty Patients.

Authors:  Gabriella Fabbrocini; Katlein França; Torello Lotti; Claudio Marasca; Maria Carmela Annunziata; Sara Cacciapuoti; Anna Masarà; Marco Romanelli; Jacopo Lotti; Uwe Wollina; Georgi Tchernev; Nicola Zerbinati
Journal:  Open Access Maced J Med Sci       Date:  2018-01-07

9.  Hidradenitis Suppurativa in Kuala Lumpur, Malaysia: A 7-Year Retrospective Review.

Authors:  Moonyza Akmal Ahmad Kamil; Azura Mohd Affandi
Journal:  Dermatol Res Pract       Date:  2018-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.